Kamran Alam
2021 - Taysha Gene Therapies
In 2021, Kamran Alam earned a total compensation of $1.8M as Chief Financial Officer at Taysha Gene Therapies, a 67% decrease compared to previous year.
Compensation breakdown
| Option Awards | $1,412,006 |
|---|---|
| Salary | $390,000 |
| Other | $5,515 |
| Total | $1,807,521 |
Alam received $1.4M in option awards, accounting for 78% of the total pay in 2021.
Alam also received $390K in salary and $5.5K in other compensation.
Rankings
In 2021, Kamran Alam's compensation ranked 6,430th out of 12,406 executives tracked by ExecPay. In other words, Alam earned more than 48.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,430 out of 12,406 | 48th |
Division Manufacturing | 2,750 out of 5,492 | 50th |
Major group Chemicals And Allied Products | 1,214 out of 2,368 | 49th |
Industry group Drugs | 1,082 out of 2,089 | 48th |
Industry Biological Products, Except Diagnostic Substances | 260 out of 452 | 43rd |
Source: SEC filing on April 28, 2022.
Alam's colleagues
We found two more compensation records of executives who worked with Kamran Alam at Taysha Gene Therapies in 2021.
News
Taysha Gene Therapies CEO Sean Nolan's 2023 pay slips 20% to $1.5M
April 18, 2024
Taysha Gene Therapies CEO RA Session's 2022 pay falls 57% to $2M
May 8, 2023
Taysha Gene Therapies CEO RA Session's 2021 pay slips 3% to $4.6M
April 28, 2022
Inotek Pharmaceuticals CEO Gaurav Shah's 2019 pay falls 39% to $3.9M
April 24, 2020
Aquinox Pharmaceuticals CEO Jonathan Drachman receives $3.8M in 2019
March 24, 2020
Aquinox Pharmaceuticals CEO David Main's 2018 pay jumps 39% to $4.2M
October 2, 2019